Videos

Zangoglia shared advantages physical therapies may offer in treating people with fibromyalgia.

Kimura highlighted some of her ongoing research tackling high priority questions in JIA.

Recent phase 3 trials reveal promising results for Duravancinib in treating psoriatic arthritis, showcasing efficacy and a strong safety profile.

Tonix Pharmaceutical's therapy has a PDFUA date of August 15, 2025.

Zasocitinib recently demonstrated better ACR responses than placebo in new trial data.

Buttgereit discussed notable findings from the SELECT-GCA trial

Nowak also shared his outlook on research in myasthenia gravis in the next 5 years.

July is Juvenile Idiopathic Arthritis Month and Onel discussed complexities of transitioning care.

July is Juvenile Arthritis Month and Onel discussed complexities of transitioning care.

Mease described his real-world experience with using bimekizumab in the clinic for treating PsA and AxSpA.

Rilzabrutinib shows promising remission rates in IgG4-related disease with minimal glucocorticoid use, offering a safer oral treatment option.

New findings highlight upadacitinib's effectiveness in treating giant cell arteritis, showcasing lower infection rates and improved glucocorticoid tapering strategies.

Mease outlined positive efficacy and safety findings from multiple long-term follow-up trials of the biologic in people with PsA and AxSpA.

Delayed specialist referral can result in decades of unnecessary pain and joint damage for patients with gout.

Gout should be treated as a chronic disease, not just an episodic flare condition.

Medication adherence, access, and comorbidity management are critical to achieving target uric acid levels.

Elevated uric acid is modifiable, and long-term remission is attainable with appropriate pharmacologic and lifestyle interventions.

Gout is a systemic metabolic disease requiring proactive, individualized treatment plans beyond dietary modification.

Gout and CKD share a bidirectional relationship that complicates management and demands multidisciplinary care.

Uncontrolled gout is a progressive, genetically driven, systemic condition that requires individualized, evidence-based urate-lowering therapy and close clinical monitoring.

Sayna Norouzi, MD, reflects on the recent progress in the therapeutic pipeline for lupus nephritis.

Sayna Norouzi, MD, discusses results from a pair of trials examining QoL in patients with lupus from ERA 2025.

Nowak discussed some of the unique advantages inebilizumab offers for this population.

Blockmans discussed data supporting upadacitinib’s new indication and why the approval is important for patients with giant cell arteritis.

Mease discussed recent research on what matters in PsA care between patients and clinicians.

Mease discussed the expanding treatment landscape for PsA and how the field is integrating new biologics.

Furie discussed topline data from the REGENCY trial and key secondary endpoints.

Furie discussed his experiences in evaluating therapies such as rituximab and now obinutuzumab for lupus nephritis.

Davidow discussed how a new cohort study has helped support findings of an older European study and the need for a prospective trial to confirm the increased risk.